Catalent Biologics, a Somerset-based provider of drug delivery solutions, said it is expanding its operations in Indiana with the $50 million addition of a third high-speed vial line at its Bloomington facility.
The line is expected to be operational by April, and add capacity to support the growing pipeline of clinical programs and commercial launches at the site, Catalent said in a news release. It will be able to produce up to 80 million vials annually.
“The industry has seen an increased demand for vial filling of biologic drugs, which has been compounded by the accelerated development of vaccine and therapeutic candidates to address the COVID-19 pandemic,” Mike Riley, region president, biologics, North America, said in a prepared statement. “Catalent’s continued investment in this capacity will allow us to remain flexible and continue to support the growth of our customers’ programs.”
This is the third major investment in two years at the site, Catalent said.